In clinical research the giving of consent by the patient often lies within the context of illness or the doctor/patient relationship.
Introduction
Clinical research is necessary to establish the safety and efficacy of a therapy. It may include, for example, the testing of nursing or physiotherapy techniques, as well as the testing of new drugs, the focus of this paper.
Clinical testing of a new drug is required by the Medicines Control Agency (MCA) before a product licence for that drug can be given. As the drug is being tested for safety and efficacy, patients taking part will be put at risk of unknown side-effects and may also be randomised to receive either the unproven drug or a placebo. When we enter a patient into such a clinical trial we are normally testing a drug appropriate to his or her condition. However, because of randomisation we may not always be selecting a particular drug for a particular patient's needs. If the comparator drug is a placebo then we may not be acting in that patient's best interests. In some cases the patient is being used as a means to an end: establishing the safety and efficacy of a new drug for the benefit of future patients. The justification for this is that the only way to establish the most effective and safe treatments to improve health (desired by most members of society) is by clinical research.' By consenting, the patient Key words Consent; voluntary; clinical research knowingly agrees to this goal and makes it his own, becoming an active participant in the research so that it cannot then be said that the patient is being used as a means to an end. Clearly the quality of that consent is therefore vital.
What does clinical research mean for the patient?
The scientific gold standard for clinical research is the randomised controlled trial (RCT) which attempts to establish statistically the risk/benefit ratio of the drug by reducing bias and controlling for variables. 2 This it does by controlling the selection of well-characterised groups of patients, randomising them into treatment groups, using standardised outcome measurements performed by blinded assessors, and stipulating a population size powerful enough to answer the question being asked. Although not without criticism3 the RCT is a credible test of safety and efficacy within the medical world and some would say it would be unethical to introduce a new drug without RCT data. 4 Patients participating in an RCT will usually need to attend hospital regularly for safety and efficacy assessments -perhaps clinical examination, blood and urine samples, and possibly X-rays. Such 
Voluntariness
All decisions are made within the context and influence of people or circumstances. Thus it would be difficult (if not impossible) to define the notion of "fully voluntary" consent. There would always be arguments that further efforts could be made to reduce influences. As with competence, information and understanding the issue is whether voluntariness is adequate. Beauchamp and Childress describe voluntariness as being independent of controlling influences exerted by others and discuss coercion (the intentional use of a credible threat), manipulation (of information to influence a decision) and persuasion (convincing by presenting rational reasons). '3 This model depends largely on the intentional actions of others. It fails to address the influence of circumstances, which I believe is common in consent to clinical research and which poses an easily overlooked threat to voluntariness. For consent to research to be adequately voluntary two factors must be fulfilled: the absence of controlling influences and the ability to choose either one of at least two options.
Influences or controlling influences?
Whilst circumstances and people will always influence any decision we make, it is the responsibility of the researcher to ensure that in clinical research, these are not so strong as to be controlling. Unlike healthy volunteers, many patients invited to participate in clinical research will have an illness and the experience of illness (which may at times include pain, disability, fear of deterioration or death, physical or emotional dependence) '" and the accompanying psychological response (possibly depression, mourning, denial, anger, anxiety, passivity and regression to an invalid role) 15 may well reduce autonomy. In addition, a request to enter a research trial may of necessity come at the time of, or soon after, the shock of diagnosis. Furthermore, some patients in hospital feel vulnerable -unaware of the normal routine or what is expected of them, and reduced, as they are, to wearing night-clothes. Is it possible to make a reflective decision, free of strong influences in such a situation?
The doctor/patient relationship is centred around patients' trust that doctors act in their best interests. Thus even though the doctor has explained that treatment in the research trial is randomised and according to a strict protocol, patients often still believe that the doctor will only act in their best interests. In a recent trial 41% of patients believed there were no risks in a phase II trial of a new anti-inflammatory agent, despite being told it was unlicensed and being tested for safety.'6 So strong is this trust that patients may agree to anything the doctor suggests and even the invitation to participate may be viewed as a recommendation rather than a request. Patients may feel flattered by the request and under an obligation to help because of past care received.
For many patients the relationship is an unequal one, with the doctor being perceived as a powerful figure on whom they depend, making it difficult for them to take an unnaturally dominant role and refuse the doctor's request. Patients may fear that if they do so, the doctor will be displeased and their future care will be jeopardised. Patients Most choices in life are limited in some way but where those limits are imposed by others then the quality of the consent, being deliberately constrained, may be morally unacceptable.
We have looked at influences on the patient and limitations of options, but in practice are these strong enough to make it difficult for the patient to refuse consent? Refusal rates are low, with none at all in recent years in a neighbouring unit (personal communication) and in our own unit, in one study only four out of 28 patients refused.'6 We compared these four patients who declined to enter a phase III trial of a specific anti-rheumatoid drug ("refusers") with 17 patients who consented to take part in a similar Phase II trial ("consenters"). The consenters rated how difficult it would have been for them to say "no" if they had wanted to refuse and the refusers rated how difficult it actually was (10 cm visual analogue scale [VAS] , very easy to very difficult). There was a significant difference between the consenters' median score (0 9, range 0-5 4) and the refusers' (7- The doctor/patient relationship Interventions here might allow the patient to step back from the relationship and consider the proposal in a more detached manner. This could be done by using a researcher/doctor as well as a carer/doctor, by using a patient advocate or by recruiting patients in groups. Separating the doctors into researcher/doctors and carer/doctors'8 may allow patients to feel less anxious about future care if they refuse. However, the doctors are likely to be, or to become, close colleagues; the carer/doctor will have to be responsible for recruitment, which involves him in the research; the researcher/doctor will need to know about the patient's care; and both doctors will need to deal with clinical problems as they arise, thus causing practical problems to arise as a result of creating this split. In therapeutic research, care and research are so closely interlinked that it is impractical and impossible not to mix the two.
A patient advocate might ask questions on the patients' behalf, act as an impartial sounding board, and deter the doctor from pressurising or hurrying the patient. A lay advocate (friend or relative) might not be able to interpret technical details any better than the patient, might also be in awe of the perceived power of the doctor, and might influence the patient by the strength of their own relationship. A non-doctor health care professional might be well suited to advocacy because of his or her familiarity with the health care system, rapport with patients and ability to interpret technical data. However, such a professional may be seen as part of the doctor's team and may well be employed by the doctor so that he or she has a vested interest in encouraging recruitment. However, a trained advocate, perhaps funded by the health authority or trust, could be specifically trained and supervised by the research ethics committee. Such posts, separate from any research or care team, have the potential to develop into an independent advocacy system.
Talking to patients about clinical research in groups rather than individually may reduce pressure on patients -more outspoken patients may ask questions which others are reluctant to voice. However, patients may also find it difficult to go against the group decision if they do not agree with it.
Selection of patients
It has been suggested that we should first approach patients who are best able to understand the research, and who are most highly motivated and least captive, such as health care professionals who have the particular disease in question."9 The numbers in this group are likely to be so small as to make research impractical and where there is a link between educational level and disease, selecting highly educated subjects might bias the study.
Education of researchers
Education of health care professionals in research ethics and obtaining consent should ease pressure on patients by increasing the researchers' awareness. This is gradually happening as nursing and medical schools include medical ethics in their curricula.
Information to patients
Specific trial information sheets are vital and patients must have time to read and discuss them. However, as they are written by the researchers who wish the patient to consent there is the real possibility that they will be biased. Consumers for Ethics in Research (CERES) produce a standard leaflet on medical research which is not written in relation to specific projects.20 Having seen this leaflet and following our own research into consent, we have developed a Patient's Guide to Medical Research (figure 1) which is given to all rheumatology patients as they are invited to participate in clinical research, alongside the specific trial information sheets.2' It is independent of any single researcher or research trial, is designed to cover many of the issues raised in this article and has an "easy" readability level. 22 We have made other changes to the consent process, including giving the responsibility for information-giving and initial interview and consent to the research nurses, who are perhaps seen as less powerful figures than the doctor. We give patients at least 48 hours to reflect on the proposal and encourage them to discuss it with family, friends and GP, before telephoning them to discuss the trial, answer questions and take their decision, which is passed on to the doctor on their behalf. We believe that these strategies reduce the difficulty patients experience in declining to take part in research and we will be assessing this in future trials. 
Conclusion

